All In Biotech

Drug Trial Radar · NCT00720811

Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs

Last checked: Nov 19, 2026Latest source record: Mar 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,456

Actual

Start

Oct 2009

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Mbarara University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Makerere University; Ministry of Health, Uganda; Navrongo Health Research Centre, Ghana; National Malaria Research and Training Centre, Burkina Faso
First posted
Jul 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the value of incorporating a malaria RDT based strategy in HMM. The primary activity of the study wil be a two armed cluster randomised trial in two study sites in Uganda, one in Ghana and one in Burkina Faso. One of the Uganda sites is highly endemic and the other meso-endemic for malaria. In one arm the children will be treated presumptively for malaria with ACT (control arm) and the other arm the children will receive ACT only when they have a positive RDT result (implementation arm). The children in the implementation arm will also receive antibiotics if they have a raised respiratory rate. The primary outcome will be the recovery rate in the intervention arm compared to that of the control arm on Day 3. In addition, an acceptability assessment of RDTs in the community will be undertaken both before and after the intervention trial and a cost-effectiveness analysis of the RDT strategy will also be completed. For a sub-sample, microscopy slides will also be taken on Day 0 to demonstrate comparable levels of endemicity in control and intervention groups. These activities will be carried out over a two year period.

Conditions

  • Malaria
  • Pneumonia

Interventions

  • Artemether-lumefantrine combinationDrug

    20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days

  • amoxycillinDrug

    amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2

  • paracetamolDrug

    paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days

  • malaria rapid diagnostic test, respiratory rate timerDevice

    malaria dipstick, and breath timer

  • Artemether-lumefantrine combinationDrug

    20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recovery rate from fever at Day 3Time frame: Day 3

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Sapone Site

    Saponé, Burkina Faso

  • Kassena Nankana Site

    Kassane, Ghana

  • Iganga Site

    Iganga, Uganda

  • Mbarara Site

    Mbarara, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.